AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

INHANCE Stemless Reverse Shoulder IDE

RecruitingNAAges 22 Years - anyAllDePuy Orthopaedics
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

2:1 Randomized, Controlled, Multi-Center, Prospective, Pre-Market Study of the INHANCE Stemless Reverse Cementless Total Shoulder.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Individuals requiring reverse total shoulder replacement for a severely painful, disabling, arthritic joint (i.e. osteoarthritis, post-traumatic arthritis and rotator cuff arthropathy). 2. Individuals who are anatomically and structurally suited to receive the implants and have a functional deltoid muscle. 3. Individuals who are able to read and comprehend the informed patient consent document and are willing and able to provide informed patient consent for participation in the study and have authorized the transfer of their information to DePuy Synthes. 4. Individuals who are willing and able to return for follow-up as specified by the study protocol. 5. Individuals who are a minimum age of 22 years at the time of consent. 6. Individuals who are willing and able to complete the Patient Reported Outcome Measure questionnaires (PROMs) as specified by the study protocol. Exclusion Criteria: 1. BMI \> 40 kg/m2 2. Individuals have active, uncontrolled local infection or systemic infection. 3. Patients who have not reached skeletal maturity, regardless of age. 4. Either preoperatively or intraoperatively and per standard of care medical assessment, bone stock in the proximal humerus or glenoid fossa is determined to be inadequate for supporting the INHANCE humeral stemless components (NOTE: exclusion applies to both arms of the study, i.e., bone stock to be evaluated independent of randomized treatment assignment). 5. Intraoperatively and per treating physician's assessment of bone quality, bone is determined to be too soft or porous to support the implant or that is too hard or brittle to allow for proper bone preparation and fixation, i.e. osteoporosis or sclerotic bone, or tumor(s) of the supporting bone structure, where there could be considerable migration of the prosthesis and/or a chance of fracture of the humerus or glenoid. 6. Fractures of the proximal humerus that could compromise the fixation of the INHANCE reverse humeral stemless components. 7. Patients who have undergone previous treatment on the study shoulder that may compromise fixation of the INHANCE reverse humeral stemless component. 8. Revision of a failed hemi, total or reverse shoulder arthroplasty. 9. Patient is receiving, or is scheduled to receive, treatment that the Investigator considers could affect bone quality, such as chemotherapy or high dose corticosteroids. 10. Individuals who are bedridden per the Investigator's determination. 11. Individuals that have participated in a clinical investigation with an investigational product (drug or device) in the last three months. 12. Individuals currently involved in any personal injury litigation, medical-legal or worker's compensation claims. 13. Individuals, in the opinion of the Investigator, who are drug or alcohol abusers or have psychological disorders that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements. 14. Patients with a known medical condition that the Investigator believes would impact the study outcomes (including, but not limited to osteomyelitis, Paget's disease, neuropathies such as Charcot's disease, metastatic or neoplastic disorders). 15. Patient has a medical condition with less than 2 years life expectancy. 16. Patients who are known to be pregnant or breastfeeding. 17. Known polyethylene and/or metal sensitivity or allergy. 18. Contralateral side has been enrolled in the study or has received a total shoulder operation within the last 6 months 19. Otherwise determined by the investigator to be medically unsuitable for participation in this study 20. Patient is a member of a vulnerable population (i.e., incarcerated individuals - those incarcerated for at least one month and considered to be an inmate)
๐Ÿ’Š

What it tests

  • Reverse Total Shoulder
๐Ÿ“

Where

15 sites
Orthopedic Center of Palm Beach County
Atlantis, United States
Boston Bone & Joint Institute BBJI Formerly BSSC
Waltham, United States
Trinity Health Grand Rapids
Grand Rapids, United States
Missouri Orthopaedic Institute (MOI)
Columbia, United States
OrthoCarolina Research Institute Charlotte
Charlotte, United States
Duke Orthopaedics of Raleigh
Raleigh, United States
Crystal Clinic Orthopaedic Center
Akron, United States
Lindner Research Center
Cincinnati, United States

โ€ฆand 7 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy